RNA Edge System
Optimizing expression of RNA therapies. Go from sequence to validated candidates in a matter of weeks.
A lab-in-the-loop platform for AI optimization of RNA therapies
Expression profile is a primary determinant of therapeutic success, but most RNA sequences are still optimized using outdated single-variable approaches, leaving significant performance potential unrealized. Achieving high expression and durability requires balancing multiple interdependent factors simultaneously: translation dynamics, RNA secondary structure, and genetic element interactions.
RNA Edge was built to solve this multi-dimensional design problem. It's a fully integrated system for optimization of expression profile, with every design validated in application-relevant cell types.
We deliver high-confidence RNA designs in weeks.
Benefits of RNA Edge
End-to-end RNA optimization: AI sequence optimization, novel genetic parts, and experimental validation to improve expression profile.
Broad therapeutic applicability: Supports linear mRNA and circular RNA across cell therapy, genome editing, and vaccines.
Proven performance: Validated in large biopharma programs for CAR and Cas9.
System performance
Data-driven computational and synthetic biology, validated in the lab.
RNA Edge combines proprietary computational models and high-performance genetic parts with integrated screening to deliver validated improvements across the variables that determine therapeutic success.
Precise control to drive therapeutic success
Expression profile is a primary determinant of therapeutic success, but achieving the right level, timing, and cell specificity requires optimizing across multiple interdependent biological factors simultaneously. RNA Edge combines proprietary computational models, high-performance genetic parts, and integrated lab screening to systematically explore design space and deliver high-performing candidates across every axis of expression.
Key capabilities
Multi-objective codon optimization: Up to 9x higher expression by optimizing multiple biological factors.
Genetic parts: Internal ribosome entry site (IRES) and untranslated region (UTR) design and screening capabilities.
Validation in relevant cells: Integrated in vitro screening in application-relevant cell models provides greater insight into real-world therapeutic performance.
From sequence to delivery of top candidates
RNA Edge takes your program from sequence design through wet lab validation in weeks, delivering high confidence, data-backed candidates.
